FY2030 Earnings Estimate for NMRA Issued By HC Wainwright

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Neumora Therapeutics in a report issued on Monday, January 26th. HC Wainwright analyst D. Tsao forecasts that the company will earn $2.02 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).

A number of other research firms have also recently weighed in on NMRA. Leerink Partners started coverage on Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday. Stifel Nicolaus lifted their price target on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a report on Monday, November 17th. Needham & Company LLC increased their price objective on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Finally, Guggenheim raised Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.13.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $2.04 on Tuesday. Neumora Therapeutics has a twelve month low of $0.61 and a twelve month high of $3.25. The firm has a market capitalization of $340.86 million, a price-to-earnings ratio of -1.39 and a beta of 3.22. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The firm’s fifty day simple moving average is $2.06 and its 200 day simple moving average is $1.97.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Daljit Singh Aurora sold 114,703 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total transaction of $307,404.04. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 26.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Legacy Private Trust Co. boosted its position in Neumora Therapeutics by 35.7% during the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in Neumora Therapeutics during the third quarter valued at approximately $1,512,000. Public Employees Retirement System of Ohio acquired a new position in Neumora Therapeutics in the 3rd quarter valued at approximately $44,000. Millennium Management LLC boosted its stake in shares of Neumora Therapeutics by 63.1% during the 3rd quarter. Millennium Management LLC now owns 2,008,248 shares of the company’s stock valued at $3,655,000 after buying an additional 776,856 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Neumora Therapeutics by 92.5% during the 3rd quarter. Bank of America Corp DE now owns 137,429 shares of the company’s stock valued at $250,000 after buying an additional 66,049 shares during the period. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.